Lab Head at Baker Heart & Diabetes Institute, Australia
Professor David Greening is an internationally recognized biomedical scientist specializing in molecular proteomics and extracellular vesicle (EV) biology. He serves as Head of Molecular Proteomics at the Baker Heart & Diabetes Institute and holds the prestigious Helen Amelia Hains Fellowship. He is also Director of the Proteomics & Metabolomics Platform at La Trobe University, with affiliate appointments at Monash University and the University of Melbourne. His research focuses on using advanced mass spectrometry and multi-omics technologies to understand complex intercellular communication, particularly in cardiovascular disease and cancer. With a Ph.D. from the University of Melbourne in collaboration with the Ludwig Institute for Cancer Research, and postdoctoral training at leading institutions including WEHI and the Institute for Systems Biology in the USA, Professor Greening has built a distinguished academic and translational research career. He has authored over 146 peer-reviewed publications, received numerous national and international awards, and actively collaborates with industry to advance EV-based diagnostics and therapeutics.
Academic Profile
SCOPUS
ORCID
GOOGLE SCHOLAR
Education
Professor David Greening completed his Bachelor of Science with Honours at the University of Melbourne, where he developed a strong foundation in biomedical science and molecular biology. He went on to earn his Ph.D. from the University of Melbourne in collaboration with the Ludwig Institute for Cancer Research, focusing on cancer biology, proteomics, and cellular signaling pathways. Following his doctoral studies, he undertook advanced postdoctoral training at several prestigious institutions, including the Walter and Eliza Hall Institute of Medical Research (WEHI), the Institute for Systems Biology in Seattle, USA, and La Trobe University in Melbourne. These experiences further deepened his expertise in high-throughput proteomics, biomarker discovery, systems biology, and translational medicine, laying the groundwork for his future leadership in molecular proteomics and extracellular vesicle research.
Experience
Professor David Greening has built an outstanding career as a biomedical scientist, currently serving as the Head of Molecular Proteomics at the Baker Heart & Diabetes Institute and holding the prestigious Helen Amelia Hains Fellowship. He is also the Director of the Proteomics & Metabolomics Platform at La Trobe University, with affiliate academic appointments at Monash University and the University of Melbourne. His professional experience spans leadership in advanced proteomics, systems biology, and extracellular vesicle (EV) research, particularly focusing on cardiovascular biology and cancer. Since joining the Baker Institute in 2019, Professor Greening has established a high-impact research program integrating mass spectrometry, nanobiotechnology, lipidomics, and bioinformatics to decode intercellular signaling and EV-mediated mechanisms in health and disease. He has led numerous industry collaborations with leading biotech and pharmaceutical companies including Takeda, Thermo Fisher, CSL, VivaZome, and Tithon Biotech. In addition to his research leadership, he has served as President of the Australian and New Zealand Society for Extracellular Vesicles and is Chair of the ISEV2024 conference. His translational efforts have contributed to the development of novel diagnostics and therapeutic strategies, advancing the clinical and commercial potential of EV-based technologies.
Research Interests
Professor David Greening’s research interests center on the dynamic field of extracellular vesicles (EVs), molecular proteomics, and systems biology, with a strong emphasis on cardiovascular biology, regenerative medicine, and cancer. He is particularly focused on understanding the complex roles of EVs in intercellular communication, their molecular architecture, and their potential as biomarkers and therapeutic vehicles. His work employs advanced mass spectrometry and multi-omics technologies—including proteomics, lipidomics, and metabolomics—to unravel the intricate signaling networks governing heart disease, tissue remodeling, and immune responses. Professor Greening is also deeply engaged in the development of EV-based diagnostic tools and acellular therapeutics, aiming to translate molecular insights into clinical applications. His interdisciplinary approach bridges basic science with translational outcomes, advancing the frontiers of precision medicine and next-generation healthcare solutions.
Awards
Professor David Greening has received numerous prestigious awards in recognition of his pioneering work in proteomics and extracellular vesicle (EV) research. In 2024, he was honored as a Lifetime Member of both the International Society for Extracellular Vesicles (ISEV) and the Australia and New Zealand Society for Extracellular Vesicles. That same year, he was presented with the ISEV Emerging Leader Award and was recognized among the Top 250 Researchers in all scientific fields in Australia by the Australian Research Magazine, which also acknowledged him as a national field leader in proteomics and protein chemistry from 2021 to 2025. His global impact was further recognized in 2023 when he was listed among Stanford University’s top 1% most-cited researchers and received Wiley’s Top 0.1% Citation Impact Award. These accolades underscore Professor Greening’s exceptional contributions to biomedical science, translational proteomics, and his leadership in advancing the clinical utility of extracellular vesicles.
Publications 📚
Cited: 10265
Cited: 1713
Cited: 1446
Cited: 1398
Cited: 981
Cited: 848
Conclusion
Prof. David Greening’s transformative research, translational impact, and sustained international leadership epitomize the essence of the Innovative Research Award. His ability to bridge fundamental biology with clinical application and his success in commercializing scientific breakthroughs position him as a premier candidate for this distinguished recognition.